|
1
|
Smallridge RC: Approach to the patient
with anaplastic thyroid carcinoma. J Clin Endocrinol Metab.
97:2566–2572. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Akaishi J, Sugino K, Kitagawa W, et al:
Prognostic factors and treatment outcomes of 100 cases of
anaplastic thyroid carcinoma. Thyroid. 21:1183–1189. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sugitani I, Miyauchi A, Sugino K, Okamoto
T, Yoshida A and Suzuki S: Prognostic factors and treatment
outcomes for anaplastic thyroid carcinoma: ATC research consortium
of Japan cohort study of 677 patients. World J Surg. 36:1247–1254.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cabanillas ME, Waguespack SG, Bronstein Y,
Williams MD, Feng L, Hernandez M, Lopez A, Sherman SI and Busaidy
NL: Treatment with tyrosine kinase inhibitors for patients with
differentiated thyroid cancer: the M. D. Anderson experience. J
Clin Endocrinol Metab. 95:2588–2595. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Benvenga S: Emerging therapies in sight
for the fight against dedifferentiated thyroid cancer. J Clin
Endocrinol Metab. 96:347–350. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rosove MH, Peddi PF and Glaspy JA: BRAF
V600E inhibition in anaplastic thyroid cancer. N Engl J Med.
368:684–685. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nobuhara Y, Onoda N, Yamashita Y, Yamasaki
M, Ogisawa K, Takashima T, Ishikawa T and Hirakawa K: Efficacy of
epidermal growth factor receptor-targeted molecular therapy in
anaplastic thyroid cancer cell lines. Br J Cancer. 92:1110–1116.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu D, Hou P, Liu Z, Wu G and Xing M:
Genetic alterations in the phosphoinositide 3-kinase/Akt signaling
pathway confer sensitivity of thyroid cancer cells to therapeutic
targeting of Akt and mammalian target of rapamycin. Cancer Res.
69:7311–7319. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Onoda N, Nakamura M, Aomatsu N, Noda S,
Kashiwagi S and Hirakawa K: Establishment, characterization and
comparison of seven authentic anaplastic thyroid cancer cell lines
retaining clinical features of the original tumor. World J Surg.
38:688–695. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wiseman SM, Masoudi H, Niblock P, Turbin
D, Rajput A, Hay J, Bugis S, Filipenko D, Huntsman D and Gilks B:
Anaplastic thyroid carcinoma: expression profile of targets for
therapy offers new insights for disease treatment. Ann Surg Oncol.
14:719–729. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rusinek D, Szpak-Ulczok S and Jarzab B:
Gene expression profile of human thyroid cancer in relation to its
mutational status. J Mol Endocrinol. 47:R91–R103. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xing M, Alzahrani AS, Carson KA, et al:
Association between BRAF V600E mutation and mortality in patients
with papillary thyroid cancer. JAMA. 309:1493–1501. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim TH, Park YJ, Lim JA, et al: The
association of the BRAF(V600E) mutation with prognostic factors and
poor clinical outcome in papillary thyroid cancer: a meta-analysis.
Cancer. 118:1764–1773. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Garcia-Rostan G, Zhao H, Camp RL, Pollan
M, Herrero A, Pardo J, Wu R, Carcangiu ML, Costa J and Tallini G:
Ras mutations are associated with aggressive tumor phenotypes and
poor prognosis in thyroid cancer. J Clin Oncol. 21:3226–3235. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vasko V, Ferrand M, Di Cristofaro J,
Carayon P, Henry JF and de Micco C: Specific pattern of RAS
oncogene mutations in follicular thyroid tumors. J Clin Endocrinol
Metab. 88:2745–2752. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Santarpia L, El-Naggar AK, Cote GJ, Myers
JN and Sherman SI: Phosphatidylinositol 3-kinase/akt and
ras/raf-mitogen-activated protein kinase pathway mutations in
anaplastic thyroid cancer. J Clin Endocrinol Metab. 93:278–284.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu Z, Hou P, Ji M, Guan H, Studeman K,
Jensen K, Vasko V, El-Naggar AK and Xing M: Highly prevalent
genetic alterations in receptor tyrosine kinases and
phosphatidylinositol 3-kinase/akt and mitogen-activated protein
kinase pathways in anaplastic and follicular thyroid cancers. J
Clin Endocrinol Metab. 93:3106–3116. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xing M: Genetic alterations in the
phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.
Thyroid. 20:697–706. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
García-Rostán G, Costa AM, Pereira-Castro
I, Salvatore G, Hernandez R, Hermsem MJ, Herrero A, Fusco A,
Cameselle-Teijeiro J and Santoro M: Mutation of the PIK3CA gene in
anaplastic thyroid cancer. Cancer Res. 65:10199–10207. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang ZG, Fukazawa T, Nishikawa T, et al:
RAD001 offers a therapeutic intervention through inhibition of mTOR
as a potential strategy for esophageal cancer. Oncol Rep.
23:1167–1172. 2010.PubMed/NCBI
|
|
21
|
Xu DZ, Geng QR, Tian Y, et al: Activated
mammalian target of rapamycin is a potential therapeutic target in
gastric cancer. BMC Cancer. 10:5362010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Faustino A, Couto JP, Pópulo H, Rocha AS,
Pardal F, Cameselle-Teijeiro JM, Lopes JM, Sobrinho-Simões M and
Soares P: mTOR pathway overactivation in BRAF mutated papillary
thyroid carcinoma. J Clin Endocrinol Metab. 97:E1139–E1149. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jin N, Jiang T, Rosen DM, Nelkin BD and
Ball DW: Dual inhibition of mitogen-activated protein kinase kinase
and mammalian target of rapamycin in differentiated and anaplastic
thyroid cancer. J Clin Endocrinol Metab. 94:4107–4112. 2009.
View Article : Google Scholar : PubMed/NCBI
|
